FDA Turns Back To CME as Opioid Control Tool

Continuing medical education has been under attack in Washington in recent years, criticized as representing a way around FDA’s control of medical promotion. Now, FDA is turning back to CME as the keystone to controlling a tough drug overuse/abuse situation.

More from Agency Leadership

More from Pink Sheet